A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers: Difference between revisions
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==CSL-112 Trial - Phase 1== ===Objective=== To measure the biomarkers of cholesterol movement following a single and multiple...") |
Rim Halaby (talk | contribs) No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To measure the biomarkers of cholesterol movement following a single and multiple infusions of CSL-112 in healthy subjects. | To measure the biomarkers of cholesterol movement following a single and multiple infusions of CSL-112 in healthy subjects. | ||
==Methods== | |||
36 healthy subjects were divided into 3 dosing groups: 4 once-weekly infusions of 3.4 g, 4 once-weekly infusions of 6.8 g, and 8 twice-weekly infusions of 3.4 g and biomarkers of cholesterol movement - cholesterol efflux capacity, serum preBeta1-HDL and HDL were measured. | 36 healthy subjects were divided into 3 dosing groups: 4 once-weekly infusions of 3.4 g, 4 once-weekly infusions of 6.8 g, and 8 twice-weekly infusions of 3.4 g and biomarkers of cholesterol movement - cholesterol efflux capacity, serum preBeta1-HDL and HDL were measured. | ||
==Results== | |||
* Infusions of CSL-112 caused immediate and profound elevation in all the biomarkers. | * Infusions of CSL-112 caused immediate and profound elevation in all the biomarkers. | ||
Line 19: | Line 18: | ||
* Multiple infusions of CSL112 causes a greater efflux of cholesterol from tissues to HDL when compared with a single infusion. | * Multiple infusions of CSL112 causes a greater efflux of cholesterol from tissues to HDL when compared with a single infusion. | ||
* No observed changes in the baseline of other lipoproteins. | * No observed changes in the baseline of other lipoproteins. | ||
==Conclusion== | |||
Single and multiple infusions of CSL-112 in healthy subjects rapidly initiates the reverse cholesterol transport, and this is beneficial in rapidly lowering the risk of recurrent cardiovascular events following acute coronary syndromes.<ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851 | url = http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851 | publisher = | date = | accessdate = 16 September 2013 }}</ref> | Single and multiple infusions of CSL-112 in healthy subjects rapidly initiates the reverse cholesterol transport, and this is beneficial in rapidly lowering the risk of recurrent cardiovascular events following acute coronary syndromes.<ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851 | url = http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851 | publisher = | date = | accessdate = 16 September 2013 }}</ref> | ||
Revision as of 23:10, 17 September 2013
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers On the Web |
American Roentgen Ray Society Images of A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
FDA on A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
CDC on A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers in the news |
Blogs on A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To measure the biomarkers of cholesterol movement following a single and multiple infusions of CSL-112 in healthy subjects.
Methods
36 healthy subjects were divided into 3 dosing groups: 4 once-weekly infusions of 3.4 g, 4 once-weekly infusions of 6.8 g, and 8 twice-weekly infusions of 3.4 g and biomarkers of cholesterol movement - cholesterol efflux capacity, serum preBeta1-HDL and HDL were measured.
Results
- Infusions of CSL-112 caused immediate and profound elevation in all the biomarkers.
- Serum preBeta1-HDL elevation was up to 20-fold.
- Serum preBeta1-HDL and cholesterol efflux capacity peaked after infusion and returned to baseline at 24 hour while there was a 72 hour sustained response for serum HDL following its peak at 24-48 hours after infusion.
- Multiple infusions of CSL112 causes a greater efflux of cholesterol from tissues to HDL when compared with a single infusion.
- No observed changes in the baseline of other lipoproteins.
Conclusion
Single and multiple infusions of CSL-112 in healthy subjects rapidly initiates the reverse cholesterol transport, and this is beneficial in rapidly lowering the risk of recurrent cardiovascular events following acute coronary syndromes.[1]
References
- ↑ "http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851". Retrieved 16 September 2013. External link in
|title=
(help)